Epidemiology and treatment costs of bone metastases from lung cancer: A French prospective, observational, multicenter study (GFPC 0601)

Journal of Thoracic Oncology

Volumn 6, Issue 3, 2011, Pages 576-582

  Decroisette, Chantal ^a,k   Monnet, Isabelle ^b   Berard, Henri ^c   Quere, Gilles ^d   Le Caer, Herve ^e   Bota, Suzanna ^f   Audigier Valette, Clarisse ^g   Geriniere, Laurence ^h   Vernejoux, Jean Marc ⁱ   Chouaid, Christos ^j  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b CH Intercommunal de Créteil   (France)

^c HÔPITAL D'INSTRUCTION DES ARMÉES ROBERT PICQUÉ   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

^e CH de Draguignan   (France)

^f HÔPITAL CHARLES NICOLLE   (France)

^g CHI de Toulon   (France)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ BORDEAUX UNIVERSITY HOSPITAL   (France)

^j HÔPITAL SAINT ANTOINE   (France)

^k Hopital d'Annecy   (France)

more..

Author keywords

Biphosphonates; Bone metastases; Costs; Non small cell lung cancer; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; OPIATE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PERSONNEL; HIDDEN MARKOV MODEL; HUMAN; HYPERCALCEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SPINAL CORD COMPRESSION;

EID: 79951769748     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318206a1e3     Document Type: Article

References (20)

1. Coleman RE. Management of bone metastases. Oncologist 2000;5:463-470.
2. Kosteva J, Langer C. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Curr Opin Oncol 2008;20:155-161. (Pubitemid 351317403)
3. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-3157. (Pubitemid 46606297)
4. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal related events in patients with bone metastases from lung cancer. Oncology 2004;67:390-396.
5. Delea TE, McKiernan J, Brandman J, et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006;1:571-576. (Pubitemid 47181406)
6. DePuy V, Anstrom KJ, Castel LD, et al. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007;15:869-876. (Pubitemid 47387507)
7. Pockett RD, Castellano D, McEwan P, et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010;19:755-760.
8. Sugiura H, Yamada K, Sugiura T, et al. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 2008;466: 729-736.
9. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-584. (Pubitemid 40613323)
10. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621. (Pubitemid 38715767)
11. Hirsh V, Tchekmedyian NS, Rosen LS, et al. Clinical benefit ofzoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004;6:170-174. (Pubitemid 39618641)
12. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with bone metastasis disease from lung cancer and elevated markers of osteoclastactivity. J Thorac Oncol 2008;3:228-236. (Pubitemid 351654321)
13. De Marinis F, Eberhardt W, Harper PG, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European Expert Panel. J Thorac Oncol 2009;10:1-8.
14. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999;7:271-279. (Pubitemid 29302636)
15. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-1445.
16. McKeage K, Plosker GL. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics 2008;26:251-268. (Pubitemid 351271381)
17. Ministère de la Santé et des Solidarités. Arrêté du 27 février 2007 relatif à la classification et à la prise en charge des prestations d'hospitalisation pour les activités de médecine, chirurgie, obstétrique et odontologie et pris en application de l'article L. 162-22-6 du code de la sécurité sociale. J Officiel 2007;50:72.
18. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009;125:1705-1709.
19. Schulman K, Kohles J. Economic burden of bone metastasis disease in the U.S. Cancer 2007;109:2334-2342. (Pubitemid 46801565)
20. Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72-79. (Pubitemid 30036338)